Video
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
Author(s):
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
EP: 1.Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
EP: 2.Available Staging Systems for Cutaneous Squamous Cell Carcinoma
EP: 3.Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
EP: 4.Defining Resectability in CSCC
EP: 5.Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
EP: 6.Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
EP: 7.Evolving Treatment Paradigm of Resectable CSCC
EP: 8.Clinical Experience With Neoadjuvant IO Therapy in Melanoma
EP: 9.Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
Now Viewing
EP: 10.Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
EP: 11.CSCC: Translating Cemiplimab Data Into Practice
EP: 12.Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
EP: 13.Best Practices in Multidisciplinary Care for CSCC
EP: 14.CSCC: Escalating Therapy for High-risk Patients
EP: 15.Practical Advice on the Evolving Management of CSCC
Related Videos
Related Content
